|
| 36660823 | Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities. | Clin Infect Dis | 2023 |
| 38033982 | Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis. | | 2023 |
| 37920466 | IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors. | | 2023 |
| 38004713 | Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study. | | 2023 |
| 38079588 | Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes. | | 2023 |
| 37415770 | Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study. | | 2023 |
| 36834381 | Determinants of Depressive Symptoms in People Living with HIV: Findings from a Population-Based Study with a Gender Perspective. | | 2023 |
| 37403345 | Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands. | | 2023 |
| 36476454 | The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe. | | 2023 |
| 37052343 | Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study. | | 2023 |
| 36685382 | Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral-induced sustained virologic response. | | 2023 |
| 36990962 | Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohort. | | 2023 |
| 36790818 | Interleukin 18 (IL-18) and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1. | | 2023 |
| 37509301 | Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV. | | 2023 |
| 35056592 | SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression. | Microorganisms | 2022 |
| 35460602 | Game-changing study of second-line HIV treatment. | Lancet HIV,The | 2022 |
| 36308326 | Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens. | Journal of Antimicrobial Chemotherapy | 2022 |
| 35763360 | Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019. | Journal of Infectious Diseases | 2022 |
| 35958520 | Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. | eClinicalMedicine | 2022 |
| 36014083 | SARS-CoV-2 Vaccination Coverage and Factors Associated with Low Uptake in a Cohort of People Living with HIV. | Microorganisms | 2022 |
| 35572577 | Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens. | Frontiers in Immunology | 2022 |
| 35630517 | Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Infection. | Microorganisms | 2022 |
| 35678461 | Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. | Journal of Antimicrobial Chemotherapy | 2022 |
| 35551149 | Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2. | Journal of acquired immune deficiency syndromes (1999) | 2022 |
| 36741092 | Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees. | | 2022 |
| 35274144 | Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. | J Antimicrob Chemother | 2022 |
| 35265729 | Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review. | Open Forum Infectious Diseases | 2022 |
| 35234328 | Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort. | HIV Medicine | 2022 |
| 34438070 | Tuberculosis incidence and mortality in people living with human immunodeficiency virus: a Danish nationwide cohort study. | Clinical Microbiology and Infection | 2022 |
| 34953549 | Practical measures for SARS-CoV-2 infection prevention - Authors' reply. | Lancet Infectious Diseases, The | 2022 |
| 34889022 | The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. | HIV Med | 2022 |
| 35113346 | HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. | Current HIV/AIDS Reports | 2022 |
| 34482352 | Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus. | AIDS | 2021 |
| 34281065 | Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings. | Int J Environ Res Public Health | 2021 |
| 34280335 | Screening for SARS-CoV-2 Antigen Before a Live Indoor Music Concert: An Observational Study. | Ann Intern Med | 2021 |
| 34051886 | Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. | Lancet Infect Dis | 2021 |
| 34149139 | [Antigen-detecting rapid tests or real-time PCR, what test to use and why?] | Enfermedades Infecciosas y Microbiologia Clinica | 2021 |
| 33315694 | Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation. | Journal of acquired immune deficiency syndromes (1999) | 2021 |
| 32905581 | Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. | Clin Infect Dis | 2021 |
| 33219675 | Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers. | J Antimicrob Chemother | 2021 |
| 35237700 | Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). | Open Forum Infect Dis | 2021 |
| 34555326 | Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. | Lancet HIV | 2021 |
| 34551889 | Antigen-detecting rapid tests or real-time PCR, what test to use and why? | | 2021 |
| 34656209 | Reassessing oral lead-in for injectable long-acting HIV therapy. | Lancet HIV,The | 2021 |
| 34890019 | HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. | Current HIV/AIDS Reports | 2021 |
| 31504329 | Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study. | Clin Infect Dis | 2020 |
| 32134108 | Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. | Journal of Antimicrobial Chemotherapy | 2020 |
| 32017355 | The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. | HIV Medicine | 2020 |
| 32675562 | Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. | AIDS | 2020 |
| 33409325 | Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. | Open Forum Infect Dis | 2020 |